General Information of Drug (ID: DMD8TNK)

Drug Name
XL475 Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Preclinical [1]
Cross-matching ID
TTD Drug ID
DMD8TNK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sodium taurocholate DM3GO0J Type-2 diabetes 5A11 Phase 1/2 [2]
Bile acid DM9UZD7 Discovery agent N.A. Phase 1 [3]
PMID29649907-Compound-INT767 DMA0RI8 N. A. N. A. Patented [4]
PMID29649907-Compound-8 DMV2D5M N. A. N. A. Patented [4]
INT-767 DMRJ9P4 Hepatic fibrosis DB93.0 Preclinical [5]
INT-777 DMTPB8A Metabolic disorder 5C50-5D2Z Investigative [6]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
G-protein coupled bile acid receptor 1 (GPBAR1) TTSDVTR GPBAR_HUMAN Agonist [1]

References

1 Clinical pipeline report, company report or official report of Exelixis (2011).
2 Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.Acta Pharmaceutica Sinica B Volume 5, Issue 2, March 2015, Pages 151-157.
3 Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5718-21.
4 Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
5 FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol. 2018 Jan;29(1):118-137.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 37).